Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regeneron PharmaceuticalsLTS:0R2M +0.59%87 ROC (Joel Greenblatt) % is 32.94% as of Mar. 2026, which is 39% below its 10-year median of 54.11. GuruFocus rates LTS:0R2M with a GF Score™ of 87/100 and a GF Value™ of $910.39 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,323 Biotechnology companies, Regeneron Pharmaceuticals ranks better than 92.21% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Regeneron Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 32.94%.
The historical rank and industry rank for Regeneron Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:
LTS:0R2M'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 46.38 Med: 54.11 Max: 122.61
Current: 50.5
During the past 13 years, Regeneron Pharmaceuticals's highest ROC (Joel Greenblatt) % was 122.61%. The lowest was 46.38%. And the median was 54.11%.
LTS:0R2M's ROC (Joel Greenblatt) % is ranked better than 92.21% of 1323
companies
in the Biotechnology industry
Industry Median: -297.52
vs LTS:0R2M: 50.50
Regeneron Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -11.40% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Regeneron Pharmaceuticals ROC (Joel Greenblatt) % Related Terms
Regeneron Pharmaceuticals ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Regeneron Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R2M vs ALNY, RVMD, ONC: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Regeneron Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 32.94% mean?
Regeneron Pharmaceuticals (LTS:0R2M) has a ROC (Joel Greenblatt) % of 32.94% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Regeneron Pharmaceuticals and its competitors. This is 39% below median its historical median of 54.11. Over the past decade, Regeneron Pharmaceuticals' ROC (Joel Greenblatt) % has ranged from 46.38 to 122.61. According to the industry distribution chart, Regeneron Pharmaceuticals ranks #103 out of 1323 companies in the Biotechnology industry, placing it in the top 7.8%.
Is Regeneron Pharmaceuticals' ROC (Joel Greenblatt) % too high?
Regeneron Pharmaceuticals' current ROC (Joel Greenblatt) % of 32.94% is 39% below median its 10-year median of 54.11. Over the past 10 years, this metric has ranged from a low of 46.38 to a high of 122.61. Based on the distribution chart, Regeneron Pharmaceuticals ranks #103 out of 1323 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Regeneron Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' ROC (Joel Greenblatt) % compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, Regeneron Pharmaceuticals ranks #103 out of 1323 companies for ROC (Joel Greenblatt) %. This places Regeneron Pharmaceuticals in the top 8% of its industry — outperforming the majority of peers. Historically, Regeneron Pharmaceuticals' own ROC (Joel Greenblatt) % has ranged from 46.38 to 122.61 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current ROC (Joel Greenblatt) % is 32.94%, which is 39% below median its own 10-year median of 54.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (LTS:0R2M) is currently considered Modestly Undervalued. The stock's GF Value™ is $910.39, compared to a current price of $676.38 — trading 25.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is 32.94%, which is 39% below median its 10-year median of 54.11. Regeneron Pharmaceuticals' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Regeneron Pharmaceuticals (LTS:0R2M), the current ROC (Joel Greenblatt) % is 32.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (LTS:0R2M) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of $676.38 is trading 25.7% below its estimated GF Value™ of $910.39.
GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for LTS:0R2M:
ROC (Joel Greenblatt) %: 32.94% (39% below median its 10-year median of 54.11)
GF Value™: $910.39 vs. price of $676.38 (25.7% below fair value)
No single metric tells the full story. See the LTS:0R2M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
87GF Score
Get the complete analysis for LTS:0R2M
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R2M has been successfully added to your 
